MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on November 15, 2005; DOI: 10.1124/mol.105.018523


0026-895X/06/6902-501-508$20.00
Mol Pharmacol 69:501-508, 2006

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.105.018523v1
mol.105.018523v2
69/2/501    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Townsend, D. M.
Right arrow Articles by Tew, K. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Townsend, D. M.
Right arrow Articles by Tew, K. D.

A Glutathione S-Transferase {pi}-Activated Prodrug Causes Kinase Activation Concurrent with S-Glutathionylation of Proteins

Danyelle M. Townsend, Victoria J. Findlay, Farit Fazilev, Molly Ogle, Jacob Fraser, Joseph E. Saavedra, Xinhua Ji, Larry K. Keefer, and Kenneth D. Tew

Deptartments of Pharmaceutical Science (D.M.T.) and Cell and Molecular Pharmacology (V.J.F., M.O., J.F., K.D.T.), Medical University of South Carolina, Charleston, South Carolina; Fox Chase Cancer Center, Philadelphia, Pennsylvania (F.F.); Basic Research Program, SAIC-Frederick, Inc., Frederick, Maryland (J.E.S.); and Macromolecular Crystallography Laboratory (X.J.) and Laboratory of Comparative Carcinogenesis (L.K.K.), National Cancer Institute, Frederick, Maryland

Nitric oxide (NO) is an endogenous, diffusible, transcellular messenger shown to affect regulatory and signaling pathways with impact on cell survival. Exposure to NO can impart direct post-translational modifications on target proteins such as nitration and/or nitrosylation. As an alternative, after interaction with oxygen, superoxide, glutathione, or certain metals, NO can lead to S-glutathionylation, a post-translational modification potentially critical to signaling pathways. A novel glutathione S-transferase {pi} (GST{pi})-activated pro-drug, O2-{2,4-dinitro-5-[4-(N-methylamino)benzoyloxy]phenyl}1-(N,N-dimethylamino)diazen-1-ium-1,2-diolate (PABA/NO), liberates NO and elicits toxicity in vitro and in vivo. We now show that PABA/NO induces nitrosative stress, resulting in undetectable nitrosylation, limited nitration, and high levels of S-glutathionylation. After a single pharmacologically relevant dose of PABA/NO, S-glutathionylation occurs rapidly (<5 min) and is sustained for ~7 h, implying a half-life for the deglutathionylation process of approximately 3 h. Two-dimensional SDS-polyacrylamide gel electrophoresis and immunoblotting with a monoclonal antibody to S-glutathionylated residues indicated that numerous proteins were S-glutathionylated. Subsequent matrix-assisted laser desorption ionization/time of flight analysis identified 10 proteins, including beta-lactate dehydrogenase, Rho GDP dissociation inhibitor beta, ATP synthase, elongation factor 2, protein disulfide isomerase, nucleophosmin-1, chaperonin, actin, protein tyrosine phosphatase 1B (PTP1B), and glucosidase II. In addition, we showed that sustained S-glutathionylation was temporally concurrent with drug-induced activation of the stress kinases, known to be linked with cell death pathways. This is consistent with the fact that PABA/NO induces S-glutathionylation and inactivation of PTP1B, one phosphatase that can participate in deactivation of kinases. These effects were consistent with the presence of intracellular PABA/NO or metabolites, because cells overexpressing MRP1 were less sensitive to the drug and had reduced levels of S-glutathionylated proteins.


Received August 31, 2005; accepted November 8, 2005

Address correspondence to: Kenneth D. Tew, Medical University of South Carolina, 173 Ashley Ave., PO Box 250505, Charleston, SC 29425. E-mail: tewk{at}musc.edu




This article has been cited by other articles:


Home page
Cancer Res.Home page
D. M. Townsend, L. He, S. Hutchens, T. E. Garrett, C. J. Pazoles, and K. D. Tew
NOV-002, a Glutathione Disulfide Mimetic, as a Modulator of Cellular Redox Balance
Cancer Res., April 15, 2008; 68(8): 2870 - 2877.
[Abstract] [Full Text] [PDF]


Home page
Mol. Interv.Home page
D. M. Townsend
S-Glutathionylation: Indicator of Cell Stress and Regulator of the Unfolded Protein Response
Mol. Interv., December 1, 2007; 7(6): 313 - 324.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
M. B. West, B. G. Hill, Y.-T. Xuan, and A. Bhatnagar
Protein glutathiolation by nitric oxide: an intracellular mechanism regulating redox protein modification
FASEB J, August 1, 2006; 20(10): 1715 - 1717.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
V. J. Findlay, D. M. Townsend, T. E. Morris, J. P. Fraser, L. He, and K. D. Tew
A Novel Role for Human Sulfiredoxin in the Reversal of Glutathionylation.
Cancer Res., July 1, 2006; 66(13): 6800 - 6806.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics